BIO-TECHNE (NASDAQ: VXRT) and Vaxart (NASDAQ:VXRT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insider and Institutional Ownership

94.4% of BIO-TECHNE shares are owned by institutional investors. Comparatively, 7.6% of Vaxart shares are owned by institutional investors. 3.8% of BIO-TECHNE shares are owned by insiders. Comparatively, 44.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares BIO-TECHNE and Vaxart’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIO-TECHNE 19.50% 14.64% 9.53%
Vaxart -317.57% -195.55% -39.01%

Analyst Recommendations

This is a summary of current ratings for BIO-TECHNE and Vaxart, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIO-TECHNE 0 1 5 0 2.83
Vaxart 0 1 0 0 2.00

BIO-TECHNE presently has a consensus target price of $191.83, suggesting a potential downside of 2.80%. Given BIO-TECHNE’s stronger consensus rating and higher possible upside, equities analysts clearly believe BIO-TECHNE is more favorable than Vaxart.

Volatility and Risk

BIO-TECHNE has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.


BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.6%. Vaxart does not pay a dividend. BIO-TECHNE pays out 31.4% of its earnings in the form of a dividend.

Valuation & Earnings

This table compares BIO-TECHNE and Vaxart’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIO-TECHNE $642.99 million 11.59 $126.15 million $4.07 48.49
Vaxart $8.90 million 2.04 -$3.40 million N/A N/A

BIO-TECHNE has higher revenue and earnings than Vaxart.


BIO-TECHNE beats Vaxart on 12 of the 14 factors compared between the two stocks.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Vaxart Company Profile

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with's FREE daily email newsletter.